ofloxacin has been researched along with Infections in 10 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Infections: Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "New fluoroquinolones, as exemplified by levofloxacin, possess broad spectrum activity against many common pathogens, including the majority responsible for respiratory tract infections (RTIs), atypical pathogens and those resistant to other therapeutic regimens." | 8.82 | Clinical applications of levofloxacin for severe infections. ( Graninger, W; Zeitlinger, M, 2004) |
| " Levofloxacin and placebo patients had a cumulative rate of infection of 6% and 6% (P=0." | 5.11 | The Early Systemic Prophylaxis of Infection After Stroke study: a randomized clinical trial. ( Cervera, A; Chamorro, A; Horcajada, JP; Mensa, J; Obach, V; Planas, AM; Revilla, M; Torres, F; Vargas, M, 2005) |
| "New fluoroquinolones, as exemplified by levofloxacin, possess broad spectrum activity against many common pathogens, including the majority responsible for respiratory tract infections (RTIs), atypical pathogens and those resistant to other therapeutic regimens." | 4.82 | Clinical applications of levofloxacin for severe infections. ( Graninger, W; Zeitlinger, M, 2004) |
| " In all, 21 adverse events were recorded in 19 patients (3." | 2.66 | Safety profile of ofloxacin in elderly patients. ( Benedetti, M; Dalle Vedove, P; Fostini, R; Girelli, M; Recchia, G, 1988) |
| "The ofloxacin diffusion was investigated in 13 cirrhotic patients with spontaneous bacterial peritonitis." | 1.28 | [Diffusion of ofloxacin in infected ascitic fluid]. ( Barbare, JC; Darchis, JP; Farinotti, R; Latrive, JP; Noel, F, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Budanov, SV | 1 |
| Hall, JM | 1 |
| Torske, KR | 1 |
| Kahn, MA | 1 |
| Moreland, AA | 1 |
| Moschella, SL | 1 |
| Joshi, S | 2 |
| Maroli, S | 1 |
| Moulick, ND | 1 |
| Badhane, S | 1 |
| Sthalekar, N | 1 |
| Ambavane, V | 1 |
| Patil, R | 1 |
| Abhyankar, M | 1 |
| Dilip, P | 1 |
| Alvarez Lerma, F | 1 |
| Palomar, M | 1 |
| Olaechea, P | 1 |
| Leon, C | 1 |
| Sanchez, M | 1 |
| Bermejo, B | 1 |
| Graninger, W | 1 |
| Zeitlinger, M | 1 |
| Chamorro, A | 1 |
| Horcajada, JP | 1 |
| Obach, V | 1 |
| Vargas, M | 1 |
| Revilla, M | 1 |
| Torres, F | 1 |
| Cervera, A | 1 |
| Planas, AM | 1 |
| Mensa, J | 1 |
| Tumminello, B | 1 |
| Karaniewsky, R | 1 |
| Gutierrez-Solana, M | 1 |
| Spivey, IM | 1 |
| Latrive, JP | 1 |
| Barbare, JC | 1 |
| Darchis, JP | 1 |
| Farinotti, R | 1 |
| Noel, F | 1 |
| Fostini, R | 1 |
| Girelli, M | 1 |
| Dalle Vedove, P | 1 |
| Benedetti, M | 1 |
| Recchia, G | 1 |
1 review available for ofloxacin and Infections
| Article | Year |
|---|---|
Clinical applications of levofloxacin for severe infections.
Topics: Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; | 2004 |
3 trials available for ofloxacin and Infections
| Article | Year |
|---|---|
Efficacy and tolerability of a combination of ofloxacin and tinidazole in the management of infectious diabetic foot ulcer.
Topics: Adult; Anti-Infective Agents; Antitrichomonal Agents; Diabetic Foot; Drug Therapy, Combination; Fema | 2003 |
The Early Systemic Prophylaxis of Infection After Stroke study: a randomized clinical trial.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Body Temperature; Brain; Brain Ischemia; C-React | 2005 |
Safety profile of ofloxacin in elderly patients.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Infections; Male; Ofloxacin | 1988 |
6 other studies available for ofloxacin and Infections
| Article | Year |
|---|---|
[Safety of floracid (levofloxacin), a Russian antimicrobial, in the treatment of outpatients].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Bacterial Agents; Drugs, Generic; Female; Huma | 2009 |
Clinical-pathological conference: case 3.
Topics: Adult; Dapsone; Diagnosis, Differential; Drug Therapy, Combination; Humans; Immunologic Deficiency S | 2010 |
[Levofloxacin in patients in the ICU. Factors influencing the choice of dose and its use in combined therapy].
Topics: Anti-Infective Agents; Critical Care; Drug Therapy, Combination; Humans; Infections; Intensive Care | 2004 |
Clinical application of levofloxacin for severe infections.
Topics: Anti-Infective Agents; Humans; Infections; Levofloxacin; Ofloxacin; Severity of Illness Index | 2006 |
Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients.
Topics: Adult; Anti-Infective Agents; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Infectio | 1993 |
[Diffusion of ofloxacin in infected ascitic fluid].
Topics: Adult; Aged; Ascites; Ascitic Fluid; Diffusion; Female; Humans; Infections; Liver Cirrhosis; Male; M | 1989 |